Versant Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Versant Capital Management's CLDX Position: Q3 2026 in Review
Versant Capital Management held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 689 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1904.
Versant Capital Management first reported a position in CLDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $25.6K in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Versant Capital Management held 689 shares of Celldex Therapeutics worth $22.3K as of Q3 2026.
- Versant Capital Management left its Celldex Therapeutics share count unchanged in Q3 2026.
- Celldex Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1904 holding.
- Versant Capital Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 8 quarters since.
- Versant Capital Management's Celldex Therapeutics position peaked at $25.6K in Q2 2026.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.